Reglagene was founded based on research from Professor Laurence Hurley's labs at the University of Arizona. The company's core mission is to innovate treatments for brain diseases, specifically focusing on overcoming the challenges posed by the blood-brain barrier. Reglagene is developing a tubulin-targeting therapy that is orally administered, well-tolerated, and capable of penetrating the blood-brain barrier to treat brain cancers. Their market focus is on providing effective and accessible treatments for patients suffering from brain tumors.
Notable affiliated individuals include Professor Laurence Hurley, whose research underpins the company's technology. Reglagene has made significant strides in redefining brain cancer treatment through its small-molecule therapy that passively crosses the blood-brain barrier. This breakthrough has positioned Reglagene as a promising player in the field of brain disease treatment, potentially transforming the therapeutic landscape and improving patient outcomes.
